Hims & Hers Stock Fell 32% As Profit Slipped
Today’s big story: Could Nvidia Stock Fall 50%? Follow The Cash
Shares of Hims & Hers Health (HIMS) fell 32.2% between August 18 and November 16, 2026, while the S&P 500 lost 3.3%. The stock suffered its largest one-day drop in that stretch on November 10, falling 16.6% the session after the company reported third-quarter results and reduced its full-year adjusted EBITDA guidance. A year earlier, Hims & Hers was growing sales quickly and still making an operating profit. Which of those two still holds after that report?

Hims & Hers Now Runs At An Operating Loss
The operating profit has not held. Hims & Hers lost 7.4% of its sales on operations in the third quarter of 2026, against an operating margin of 2.0% in the third quarter of 2025.
That loss was narrower than the second quarter’s, yet the November 9 report lowered the profit outlook. Gross margin fell to 57.2% in the third quarter from 63.8% in the second, and management said most of that decline came from lower-margin branded weight loss products in its international business. Management also reduced its 2026 adjusted EBITDA guidance to $257 million to $277 million, reflecting more aggressive pricing and marketing it plans in the U.K. and Germany and the deferral of some weight loss membership revenue.
The whole fall came in the final month, as the shares lost 33.9% between October 16 and November 16, after rising about 2.6% in the two months before. Over the full three months, Cigna rose 8.4% and CVS Health fell 6.0%, so most of the drop belonged to Hims & Hers alone.
Sales At Hims & Hers Are Still Growing Quickly
Reported sales growth has held in the latest quarter. Revenue grew 48.6% from a year earlier in the third quarter of 2026, about the same pace Hims & Hers posted in the third quarter of 2025. Without about $135 million from Eucalyptus, a business it acquired in 2026, growth was about 26%.
Growth in the U.S. picked up. Management said domestic revenue rose 21% in the third quarter, up from 16% growth in the second. For the fourth quarter, management expects revenue of $875 million to $895 million, about 42% to 45% above a year earlier.
Part Of The Growth Came From Buying Eucalyptus
International revenue rose more than fourfold to $233 million in the third quarter, management said. About $135 million of that total came from Eucalyptus, which Hims & Hers acquired earlier in 2026. The rest of the international business grew nearly 80%.
Subscribers moved the other way. Hims & Hers ended the quarter with 2.8 million, 100,000 fewer than in the second quarter, after management held back marketing in its U.S. weight loss business. Management also tied the drop to brand migrations in its international markets. Management said keeping that spending lower in the fourth quarter may bring another quarter of subscriber headwinds, and it plans to put marketing money back to work ahead of the new year.
So the report changed the profit picture. Reported sales growth stayed near last year’s pace, but only with Eucalyptus included. Management narrowed its 2026 revenue outlook to $3.13 billion to $3.15 billion, up 33% to 34% from 2025. Profit is the weaker part, and the operating margin is the measure to watch when Hims & Hers reports again, expected in February 2027.
No owner could have known in August which report would bring the steepest drop. No one can call the next surprise either, but you can spread your money so that you are not betting on calling it.
Stop Guessing. Start Positioning.
No one can predict surprises like this one. The Trefis High Quality (HQ) Portfolio doesn’t try: it holds 30 quality stocks in equal weight, so no single surprise decides your result. Come see how it works.
Spot an error or want more like this? Tell us in 10 seconds.